Disopyramide
A class IA antiarrhythmic drug used to treat and prevent ventricular arrhythmias and atrial fibrillation by blocking sodium channels in the heart, slowing conduction and reducing excitability. It also has significant anticholinergic effects, causing dry mouth, urinary retention, and constipation. It has negative inotropic effects and must be used cautiously in patients with heart failure.
分子量
339.5000 g/mol
LogP
3.20
TPSA
59.20 Ų
リピンスキーの五則
適合
治療領域
作用機序
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
2D構造
Cite this structure
Embed this structure
SMILES
CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C
InChI
InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
Molecular Formula
C21H29N3O
HBD / HBA
1 / 3
回転可能結合数
8
重原子数
25
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
A class IA antiarrhythmic drug used to treat and prevent ventricular arrhythmias and atrial fibrillation by blocking sodium channels in the heart, slowing conduction and reducing excitability. It also has significant anticholinergic effects, causing dry mouth, urinary retention, and constipation. It has negative inotropic effects and must be used cautiously in patients with heart failure.
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Yes, Disopyramide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL517. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3114. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="disopyramide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/disopyramide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/disopyramide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/disopyramide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="disopyramide"></drugfyi-drug>